These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 25914745)

  • 1. The efficiency of biologic therapy in a group of patients with rheumatoid arthritis.
    Gavrilă BI; Ciofu C; Stoica V; Panaitescu E
    J Med Life; 2015; 8(1):79-84. PubMed ID: 25914745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: An observational retrospective study of 72 rheumatoid arthritis switchers.
    Lequerré T; Farran É; Ménard JF; Kozyreff-Meurice M; Vandhuick T; Tharasse C; Pouplin S; Daragon A; Le Loët X; Varin R; Vittecoq O
    Joint Bone Spine; 2015 Oct; 82(5):330-7. PubMed ID: 25864942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. VARIAR Study: Assessment of short-term efficacy and safety of rituximab compared to an tumor necrosis factor alpha antagonists as second-line drug therapy in patients with rheumatoid arthritis refractory to a first tumor necrosis factor alpha antagonist.
    Torrente-Segarra V; Acosta Pereira A; Morla R; Ruiz JM; Clavaguera T; Figuls R; Corominas H; Geli C; Roselló R; de Agustín JJ; Alegre C; Pérez C; García A; Rodríguez de la Serna A
    Reumatol Clin; 2016; 12(6):319-322. PubMed ID: 26831256
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Retention rates of adalimumab, etanercept and infliximab as first-line biotherapy agent for rheumatoid arthritis patients in daily practice - Auvergne experience.
    Soubrier M; Pereira B; Frayssac T; Fan A; Couderc M; Malochet-Guinamand S; Mathieu S; Tatar Z; Tournadre A; Dubost JJ
    Int J Rheum Dis; 2018 Nov; 21(11):1924-1932. PubMed ID: 28901727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medication effectiveness with the use of tumor necrosis factor inhibitors among Texas Medicaid patients diagnosed with rheumatoid arthritis.
    Oladapo A; Barner JC; Lawson KA; Novak S; Rascati KL; Richards KM; Harrison DJ
    J Manag Care Spec Pharm; 2014 Jul; 20(7):657-67. PubMed ID: 24967519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.
    Moots RJ; Xavier RM; Mok CC; Rahman MU; Tsai WC; Al-Maini MH; Pavelka K; Mahgoub E; Kotak S; Korth-Bradley J; Pedersen R; Mele L; Shen Q; Vlahos B
    PLoS One; 2017; 12(4):e0175207. PubMed ID: 28448562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rates of serious infections and malignancies among patients with rheumatoid arthritis receiving either tumor necrosis factor inhibitor or rituximab therapy.
    Aaltonen KJ; Joensuu JT; Virkki L; Sokka T; Aronen P; Relas H; Valleala H; Rantalaiho V; Pirilä L; Puolakka K; Uusitalo T; Blom M; Konttinen YT; Nordström D
    J Rheumatol; 2015 Mar; 42(3):372-8. PubMed ID: 25593230
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
    Zhou ZY; Griffith J; Du EX; Chin D; Betts KA; Ganguli A
    Adv Ther; 2016 May; 33(5):807-23. PubMed ID: 27084724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained Remission in Tumor Necrosis Factor Inhibitor-treated Patients with Rheumatoid Arthritis: A Population-based Cohort Study.
    Einarsson JT; Geborek P; Saxne T; Kapetanovic MC
    J Rheumatol; 2015 May; 42(5):741-8. PubMed ID: 25684762
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Variations in the metabolome in response to disease activity of rheumatoid arthritis.
    Tatar Z; Migne C; Petera M; Gaudin P; Lequerre T; Marotte H; Tebib J; Pujos Guillot E; Soubrier M
    BMC Musculoskelet Disord; 2016 Aug; 17(1):353. PubMed ID: 27549132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-TNF treatment response in rheumatoid arthritis patients with moderate disease activity: a prospective observational multicentre study (MODERATE).
    Ceccarelli F; Massafra U; Perricone C; Idolazzi L; Giacomelli R; Tirri R; Russo R; Pistone G; Ruscitti P; Parisi S; Sainaghi PP; Cacciapaglia F; Zullo A; Marino V; Migliore A; Valesini G
    Clin Exp Rheumatol; 2017; 35(1):24-32. PubMed ID: 27974105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Which factors influence radiographic progression during treatment with tumor necrosis factor inhibitors in clinical practice? Results from 930 patients with rheumatoid arthritis in the nationwide Danish DANBIO registry.
    Ørnbjerg LM; Østergaard M; Bøyesen P; Krogh NS; Thormann A; Tarp U; Poulsen UE; Espesen J; Schlemmer A; Graudal N; Kollerup G; Jensen DV; Madsen OR; Glintborg B; Christensen T; Lindegaard H; Bøhme W; Hansen A; Andersen AR; Hetland ML
    J Rheumatol; 2014 Dec; 41(12):2352-60. PubMed ID: 25274894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Risk of Hospitalized Infection Associated With Biologic Agents in Rheumatoid Arthritis Patients Enrolled in Medicare.
    Yun H; Xie F; Delzell E; Levitan EB; Chen L; Lewis JD; Saag KG; Beukelman T; Winthrop KL; Baddley JW; Curtis JR
    Arthritis Rheumatol; 2016 Jan; 68(1):56-66. PubMed ID: 26315675
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: A retrospective observational study.
    Hirata S; Li W; Defranoux N; Cavet G; Bolce R; Yamaoka K; Saito K; Tanaka Y
    Mod Rheumatol; 2015 May; 25(3):344-9. PubMed ID: 25295918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL.
    Fafá BP; Louzada-Junior P; Titton DC; Zandonade E; Ranza R; Laurindo I; Peçanha P; Ranzolin A; Hayata AL; Duarte A; Silveira IG; Costa I; Macieira JC; Guedes-Barbosa LS; Bertolo MB; Sauma MF; Silva MB; Freire M; Scheinberg MA; Fernandes V; Bianchi W; Miranda JR; Pinheiro GR; Carvalho HM; Brenol CV; Pereira IA; de Castro GR; de Morais JC; Oliveira SK; de Abreu MM; Toledo RA; Pinheiro MM; Vieira WP; Valim V;
    Clin Rheumatol; 2015 May; 34(5):921-7. PubMed ID: 25851594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
    Li N; Betts KA; Messali AJ; Skup M; Garg V
    Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Persistent periodontal disease hampers anti-tumor necrosis factor treatment response in rheumatoid arthritis.
    Savioli C; Ribeiro AC; Fabri GM; Calich AL; Carvalho J; Silva CA; Viana VS; Bonfá E; Siqueira JT
    J Clin Rheumatol; 2012 Jun; 18(4):180-4. PubMed ID: 22647860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of rituximab or tumour necrosis factor inhibitors on lung infection and survival in rheumatoid arthritis-associated bronchiectasis.
    Md Yusof MY; Iqbal K; Darby M; Lettieri G; Vital EM; Beirne P; Dass S; Emery P; Kelly C
    Rheumatology (Oxford); 2020 Oct; 59(10):2838-2846. PubMed ID: 32065634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Time-course of health status in patients with rheumatoid arthritis during the first year of treatment with infliximab.
    Ban A; Inaba M; Furumitsu Y; Okamoto K; Yukioka K; Goto H; Nishizawa Y
    Biomed Pharmacother; 2010 Feb; 64(2):107-12. PubMed ID: 19944558
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synovial features of patients with rheumatoid arthritis and psoriatic arthritis in clinical and ultrasound remission differ under anti-TNF therapy: a clue to interpret different chances of relapse after clinical remission?
    Alivernini S; Tolusso B; Petricca L; Bui L; Di Sante G; Peluso G; Benvenuto R; Fedele AL; Federico F; Ferraccioli G; Gremese E
    Ann Rheum Dis; 2017 Jul; 76(7):1228-1236. PubMed ID: 28119289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.